Refractory Metastatic Colorectal Cancer Clinical Trial
Official title:
A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
This is a multicenter, single arm, safety lead-in, Phase 2 study, using Simon's 2 stage design evaluating the safety and efficacy of TAS-102 plus nivolumab in participants with Microsatellite-stable refractory metastatic colorectal cancer Stage 1: Participants will be enrolled and after Cycle 1 treatment, they will be evaluated for the safety and tolerability of the combination therapy. Assuming a tolerated dose is confirmed additional participants evaluable for response will be enrolled and followed for a minimum of 6 months and there will be an interim analysis to assess the safety and efficacy to determine whether the second stage will open for enrollment. Stage 2: Additional participant evaluable for response assessment will be enrolled and followed for a minimum of 6 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04527068 -
QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05248048 -
NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer
|
Early Phase 1 | |
| Completed |
NCT04737187 -
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
|
Phase 3 | |
| Active, not recruiting |
NCT05205330 -
A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05733611 -
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
|
Phase 2 | |
| Recruiting |
NCT05991102 -
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer
|
N/A | |
| Recruiting |
NCT05213195 -
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06343116 -
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
|
Phase 3 |